Targeted pill tested for Tough-to-Treat bladder tumors

NCT ID NCT02657486

Summary

This small pilot study tested whether an oral drug called BGJ398 could shrink tumors in patients with a specific type of recurrent bladder cancer. It involved 4 adults whose cancer had returned after standard treatment and who had a particular genetic mutation. The goal was to see if the drug could eliminate visible tumors in the bladder lining.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.